Nature Biotechnology | Insilico’s AI-driven IPF candidate rentosertib shows potential for biological age reversal, as assessed by six proteomic aging clocks
Insilico employs AI-driven tools to uncover the link between idiopathic pulmonary fibrosis (IPF) and accelerated aging - EurekAlert!
Insilico Medicine announces Nature Medicine publication of Phase IIa results evaluating rentosertib, the novel TNIK inhibitor for idiopathic pulmonary fibrosis (IPF) discovered and designed with a pioneering AI approach - EurekAlert!
